11 results about "Z-ligustilide" patented technology

The application discloses a method for establishing a gynecological menstruation-regulating tablet fingerprint spectrum by using a high-performance liquid chromatography technology and application, by using the method, a good fingerprint spectrum is obtained, and the chromatographic peak is comprehensive, 12 fingerprint peaks are confirmed, wherein, corresponding attribution peaks of angelica sinensis, fried atractylodes macrocephala koidz, vinegar corydalis and chuanxiong are all in the gynecological menstruation-regulating tablet, and the angelica sinensis, fried atractylodes macrocephala koidz and vinegar corydalis all have exclusive peaks. By comparing with the reference substance, and combining with ultraviolet absorption spectrum characteristics, characteristic peaks of five chemical components, i.e., chlorogenic acid, ferulic acid, chuanxiongolide I, ligusticum lactone and butenyl phthalide are identified. The application further discloses a reference fingerprint spectrum of the gynecological menstruation-regulating tablet obtained by using the method, the gynecological menstruation-regulating tablet fingerprint spectrum detection method and the obtained reference fingerprint spectrum can objectively evaluate the overall quality of the gynecological menstruation-regulating tablet, and provide a research basis for quality control of the gynecological menstruation-regulating tablet.

The application discloses a composition for treating lumbar intervertebral disc herniation and repairing annulus fibrosus, relates to the technical field of traditional Chinese medicine compositions, and comprises the following raw materials: radix rehmanniae preparata, plastrum testudinis, fructus psoraleae, eucommia ulmoides oliver, walnut kernel, bee pollen, ligustilide, saikosaponin A, salvianolic acid B, ferulic acid, calycosin, stibene glycoside, prunol, loganin, hydroxysafflor yellow A and ligustilide. Experiments show that the composition can strengthen the repair of annulus fibrosus, has anti-inflammatory and analgesic effects, protects collagen, inhibits degeneration, can effectively treat lumbar intervertebral disc herniation and realize the structural repair of damaged annulus fibrosus, and provides a new technical scheme for the clinical treatment of lumbar intervertebral disc herniation.

The invention provides a method for extracting phthalide chemical components in angelica sinensis, which comprises the following steps of: firstly, shearing and emulsifying the angelica sinensis at a high speed, carrying out high-speed shearing and extraction by using petroleum ether and ethyl acetate as extraction solvents, and recovering the solvents from the extract under reduced pressure through a rotary evaporator to obtain angelica sinensis essential oil; wherein the extracted essential oil contains senkyunolide A, ligustilide and butylphthalide. Aiming at the characteristics that the phthalide component in the angelica volatile oil is thermally unstable and is easy to oxidize, the phthalide component in the angelica volatile oil can be rapidly extracted under a low-temperature condition by combining a petroleum ether-ethyl acetate solution system with a high-speed shearing, dispersing and emulsifying technology, and the activity of the angelica volatile oil can be better maintained. The method has the characteristics of low temperature, simplicity in operation, short time and low cost.

This invention relates to the field of pharmaceutical technology, specifically proposing the application of ligustilide in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating lung tumors to address the current lack of natural drugs for lung cancer prevention. Lung tumors are nitrosamine-induced carcinogenesis of lung tissue. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or alleviating and / or treating lung tumors, comprising an active ingredient and pharmaceutically acceptable excipients; wherein the active ingredient is ligustilide. Ligustilide directly targets the STING protein, activates the cGAS-STING pathway, promotes STING phosphorylation and cell-mediated immune surveillance, while simultaneously regulating ROS homeostasis and the inflammatory microenvironment, reducing nitrosamine damage to lung epithelial cells, and preventing nitrosamine-induced lung carcinogenesis.

The invention discloses a fingerprint spectrum detection method of a consistent decoction reference sample and application, and relates to the technical field of traditional Chinese medicine detection. According to the fingerprint detection method, a test solution is determined and analyzed by adopting a high performance liquid chromatography, and the conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18 chromatographic column; the column temperature is 28-32 DEG C; the detection wavelength is 0 to 25 minutes, and the wavelength is 278 to 282nm; in 25-66 minutes, the wavelength is 318-322 nm; the time is 66 to 80 minutes, and the wavelength is 278 to 282nm; the time is 80 to 90 minutes, and the wavelength is 318 to 322 nm; the mobile phase A is acetonitrile, and the mobile phase B is a 0.09-0.11 wt% phosphoric acid solution; and eluting by adopting a gradient elution procedure. According to the method, digitonin C, 4-cumaric acid, ferulic acid, rutin, verbascoside, senkyunolide I and ligustilide in the consistent decoction can be detected at a time, and the method is high in accuracy, good in repeatability, high in durability and good in specificity.

The invention discloses a pharmaceutical composition for treating acute myocardial infarction, a preparation and application. The medicine composition is prepared from raw material medicines including Z-ligustilide and chlorogenic acid, and the molar ratio of the Z-ligustilide to the chlorogenic acid is 5: (1-20). The pharmaceutical composition disclosed by the invention can be used for treating acute myocardial infarction in a synergistic manner.

The application discloses a composition for treating depression and application thereof, and the composition for treating depression comprises the following components in parts by weight: ligustilide 35-40 parts, arturn 0.5-1.5 parts and alpha-cyperone 0.1-1 part; the application firstly compounding active ingredients in Yujia pills which target 5-HT1AR and 5-HTT, and preparing a new traditional Chinese medicine efficacy component composition; in addition, the anti-depression efficacy of the active ingredients is evaluated by establishing a reserpine mouse depression model, and it is shown that the active ingredient composition screened from the 5-HT1AR and 5-HTT targets can regulate the content of monamine neurotransmitters in brain tissues to exert the anti-depression efficacy, and the in-vivo pharmacological experiment fully proves the anti-depression efficacy of the composition.

The present application belongs to the field of medicine and health care products, and particularly relates to a pharmaceutical composition for treating atherosclerosis and application thereof. The pharmaceutical composition is mainly composed of tectoridin and Z-ligustilide, and the molar ratio of the two is (1-5):(1-5). In vivo experiments are carried out on ApoE ‑ / ‑ mouse models, and the results show that after the composition is administered by gavage, it can significantly inhibit the formation of aortic plaques, reduce the necrotic core area in the plaques, and reduce the recruitment of macrophages under the vascular endothelium. The pharmaceutical composition has a clear anti-atherosclerotic effect, can effectively improve the pathological process, and is expected to be developed into a new drug for clinically treating atherosclerosis.

The invention discloses a preparation method and application of a natural Chinese herbal medicine compound feed for improving disease resistance of Tan sheep. The core is a five-in-one system of angelica sinensis, Chinese wolfberry fruits, probiotics, a slow-release carrier and a stress protective agent. The Chinese angelica is used as a core to directionally enrich ferulic acid and ligustilide, Chinese wolfberry, betaine, alpha-ketoglutaric acid and Ningxia salt-tolerant bacillus subtilis are combined, and a modified alfalfa fiber slow-release carrier containing a yeast culture and magnesium oxide is embedded. The additive amount is adjusted through grading stress states of respiratory rate and excrement form, so that the targeted release of active ingredients is realized, the anti-stress capability and intestinal health of the Tan sheep are synergistically enhanced, the disease resistance in the stress period is remarkably improved, the disease incidence rate is reduced, no drug residue exists, the preparation process is mature, and the feed is suitable for green large-scale breeding and has a wide application prospect.

The invention belongs to the technical field of cardiovascular disease treatment medicines, and particularly relates to application of ligustilide in preparation of a medicine for relieving inflammatory response after myocardial ischemia. According to the application disclosed by the invention, research finds that ligustilide can be used for remarkably inhibiting the level of S100A9 in serum, remarkably inhibiting expression of S100A9 mRNA and protein in a cardiac infarction region and expression of S100A9 in neutrophil for the first time, so that release of inflammatory factors and chemotactic factors can be effectively reduced, and occurrence of myocardial tissue inflammatory response is prevented or inflammatory response caused by myocardial ischemia is relieved; the compound can inhibit MI mouse infarction region neutrophil and mononuclear cell infiltration, and inhibit formation of NETs after MI and expression and activation of NLRP3 inflammasome, so that inflammatory response after MI can be relieved, and myocardial tissue can be protected. The application range of ligustilide in cardiovascular diseases is expanded, and a new drug choice is provided for prevention and treatment of inflammatory response after myocardial ischemia.

The invention belongs to the field of medicines, and particularly relates to application of Z-ligustilide in a medicine for treating migraine. Z-ligustilide is combined with fecal fungus transplantation (FMT), by adjusting host intestinal flora and metabolites, the community structure and metabolic function of the intestinal flora can be recovered, the level of neurotransmitters such as serotonin can be adjusted, the migraine symptom can be relieved through the multi-target effect, the clinical symptom of migraine can be improved through multiple ways through the Z-ligustilide combined fecal fungus transplantation technology (FMT), and the migraine treatment effect is improved. The treatment effectiveness is improved.